Which is better for UK investors, the FTSE 100 or the S&P 500?

Despite being home to mostly international companies, the FTSE 100 has a valuation that’s very different from the US stock market.

| More on:
The flag of the United States of America flying in front of the Capitol building

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

When I look at US stocks, I sometimes despair of the FTSE 100.

Our dear old Footsie is up 11.3% in the past five years. The period does include the pandemic and the 2020 stock market crash. So maybe that’s not too bad?

Well, the US went through exactly the same pains. But over there, the S&P 500 has gained 93.7% in the same period (at the time of writing).

Go west?

US investors have been trying to woo UK companies to cross the Atlantic and list in New York instead of London.

In June this year, Emma Walmsley, CEO of UK pharmaceuticals giant GSK (LSE: GSK) felt the need to assure the market that the company had no intention of giving up its UK listing.

She pointed out that GSK spends more than £1bn on research and development per year in this country, and employs 11,000 people. That’s even though only a small amount of its earnings come from UK sales.

Valuations

When I look at the GSK valuation, I have some sympathy for shareholders who might like to see it abandon the UK stock market.

We’re looking at a forecast price-to-earnings (P/E) ratio of 12, less than the FTSE 100 long-term average. And with earnings growth expected for the next few years, that could drop to under nine based on 2026 forecasts.

Compare that with Eli Lilly, for example, on the US stock market. That’s on a forward P/E of 57 for this year. Again, there’s earnings growth on the cards. But it would still leave the P/E at 32 for 2026.

Eli Lilly shares are worth around four to five times the value of GSK shares, on that basis.

Britain’s AstraZeneca, which still seems to be enjoying some of its Covid vaccine boost, has P/E multiples somewhere in between, in the twenties.

Dividends too

Still, if US pharma stocks are valued a lot higher than UK ones, at least the dividend situation is in our favour.

Eli Lilly is on a dividend yield of just 0.6% according to forecasts for this year. GSK, meanwhile, looks set to reward shareholders with a far juicier 3.9%. So there’s a much lower stock valuation, but 6.5 times the annual cash reward.

In fact, that reflects the two indexes as a whole.

Right now, the S&P 500 is on an average P/E of about 28 to 29 (depending on who we ask). And the average dividend yield is about 1.25%.

The FTSE 100 is valued at about half the P/E, around 14 (again depending on the source, and there’s some variation in estimates). But the forecast dividend yield is up at 3.5%.

Growth vs income

Whatever the reason for the differences, I don’t think there’s a clear case for either the FTSE 100 or the S&P 500 being generally better for investors.

Maybe the S&P is better for growth investors and the Footsie for income investors?

It has to be down to personal choice. But when making that choice, do beware that past performance is not a guarantee of future performance.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca Plc and GSK. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Down 10% in a month with a 10% yield! Is this stock a no-brainer buy for a second income?

Harvey Jones bought this FTSE 100 stock because it offered an unmissable double-digit yield. Now he's wondering whether it will…

Read more »

Investing Articles

Here’s the latest FTSE 100 dividend forecast, and it’s growing

Despite a generally good year for UK share prices so far in 2024, yields are still strong. And the dividend…

Read more »

Dividend Shares

2 dividend shares that are smashing the rest of the FTSE 100

Jon Smith flags up two dividend shares that are well ahead of the FTSE 100 average for both the dividend…

Read more »

Investing Articles

I’d love to buy this FTSE 100 value stock today

This top-tier value stock has massively trailed the FTSE 100 so far in 2024. But as inflation holds steady and…

Read more »

Investing Articles

Down 87%, is this once-famous stock set to explode like the Rolls-Royce share price?

Unlike the roaring Rolls-Royce share price, this growth stock and former household name has totally bombed. But is it due…

Read more »

Investing Articles

As investor sentiment sinks, is the stock market about to crash?

Investor confidence has dropped sharply in recent quarters, data from Saxo Bank shows. Is a stock market crash coming? And…

Read more »

Investing Articles

If I wanted to invest in Nvidia, I’d buy this FTSE 250 stock at a 12% discount

Nvidia stock has certainly rediscovered its mojo in October. However, this investor thinks there might be a better alternative in…

Read more »

US Stock

If I’d invested £1k a year ago in the S&P 500, here’s how much more I’d have versus the FTSE 100

Jon Smith details the reasons behind the difference in performance of the S&P 500 and the FTSE 100 and outlines…

Read more »